FINDINGS:
Comparison: 2023-12-19.
Lungs: No focal consolidation or suspicious pulmonary nodules. No pneumothorax. lungs are normal. Post-treatment change: volume loss.
Mediastinum: Cardiomediastinal contours within normal limits.
Pleura/Pleural spaces: No pleural effusion or pleural thickening.
Great vessels/Aorta: No thoracic aortic aneurysm or dissection.
Liver: No focal hepatic lesions. Normal attenuation. no hepatic mass.
Spleen: Normal in size and attenuation. No focal splenic lesion. tiny cyst. accessory spleen.
Pancreas: Normal pancreatic contour and enhancement. No focal mass.
Adrenal glands: Adrenal glands are normal without nodules.
Kidneys: No hydronephrosis. No enhancing renal mass. no renal mass.
GI tract/Bowel: 91 mm lobulated gastric mass at the antrum of the stomach (isoenhancing). No obstructive process. No focal bowel wall mass identified. small benign polyp.
Mesentery/Omentum: No ascites. No omental caking. no peritoneal nodularity.
Mesenteric vessels (SMA/SMV): SMA/SMV are patent without thrombosis.
Urinary bladder: Unremarkable.
Reproductive organs: No adnexal mass. Uterus/prostate within expected size for age. prostate is normal / no prostatic mass.
Lymph nodes: Enlarged mesenteric lymph node, short axis 30 mm. No pathologically enlarged lymph nodes by size criteria.
Bones/Osseous structures: No aggressive osseous lesion. No acute fracture.

IMPRESSION:
- Stomach primary malignancy at antrum of the stomach measuring approximately 91 mm.
- Findings concerning for nodal involvement.
- No definite distant metastases identified.
- RECIST 1.1 Summary:
- Target lesions (n=2; ≤2 per organ rule applied).
  • T1: Primary — 79→91 mm (longest diameter).
  • T2: Lymph node — 26→30 mm (short axis).
- SLD baseline: 105 mm.
- SLD current: 121 mm (+15.2% change).
- New lesions: absent (unequivocal).
- - RECIST 1.1 overall response category: SD.
